NADAC acquisition cost data for INVELTYS 1% EYE DROP. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 71571012128 | $103.50 | 2023-01-02 | Rx |
Generic: Loteprednol Etabonate | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $2.5M | 9,715 | 6,752 | $85.24 |
| 2020 | $4.1M | 14,378 | 9,017 | $95.62 |
| 2021 | $5.0M | 16,642 | 10,017 | $99.15 |
| 2022 | $4.8M | 15,220 | 8,637 | $102.94 |
| 2023 | $2.7M | 7,838 | 3,984 | $109.00 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| New York | $402.0K | 1,165 | 581 |
| California | $326.5K | 933 | 546 |
| Texas | $226.4K | 694 | 325 |
| Pennsylvania | $211.6K | 604 | 307 |
| Florida | $168.8K | 473 | 211 |
| North Carolina | $143.3K | 450 | 298 |
| Connecticut | $132.4K | 377 | 200 |
| Rhode Island | $107.4K | 345 | 183 |
| Massachusetts | $94.4K | 248 | 146 |
| Virginia | $89.9K | 233 | 126 |
| Georgia | $69.9K | 198 | 109 |
| Tennessee | $64.8K | 181 | 101 |
| Ohio | $62.5K | 178 | 66 |
| Delaware | $52.0K | 175 | 107 |
| New Jersey | $50.3K | 157 | 79 |
| South Carolina | $49.7K | 120 | 60 |
| Louisiana | $43.2K | 130 | 33 |
| Michigan | $43.0K | 139 | 65 |
| Missouri | $40.2K | 100 | 32 |
| Illinois | $38.0K | 115 | 55 |
| Alabama | $33.9K | 95 | 43 |
| Maryland | $30.9K | 93 | 37 |
| Oklahoma | $30.5K | 95 | 60 |
| Indiana | $27.8K | 79 | 34 |
| Kentucky | $27.5K | 47 | 20 |
| Arizona | $22.7K | 40 | 21 |
| Washington | $17.0K | 43 | N/A |
| Arkansas | $15.9K | 35 | 18 |
| Colorado | $15.9K | 45 | 16 |
| Kansas | $13.9K | 43 | 21 |
| Minnesota | $10.7K | 34 | N/A |
| Oregon | $10.6K | 32 | N/A |
| Nevada | $8.0K | 25 | 19 |
| Iowa | $6.4K | 17 | N/A |
| Hawaii | $5.3K | 14 | 11 |
| District of Columbia | $5.0K | 13 | N/A |
| Vermont | $3.6K | 11 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.